ArticleOral oncology2025
Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
Article in Oral oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Comprehensive analysis and validation of the prognostic value of glycosylation- and mitophagy-related genes for head and neck squamous cell carcinoma.Translational cancer research · 2026Article
- Oncogenic and immunomodulatory functions of SUV420H1 in HPV-negative head and neck squamous cell carcinoma.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chromatin factors, defined here as proteins that chemically modify the DNA and histones, remodel chromatin and regulate nucleosome occupancy, play central roles in the transcriptional regulation of genes and are implicated in cancer initiation and progression in multiple cancer types. To systematically investigate the genomic and expression alterations of chromatin factors in head and neck squamous cell carcinoma (HNSCC), we utilized the molecular profiles from 530 HNSCC tumor samples in the Cancer Genome Atlas (TCGA), and characterized the mutational, copy number and transcriptional alterations of 422 chromatin factors, as well as their correlation with the "cold" tumor phenotype in HPV-negative and HPV-positive HNSCC. Histone-lysine N-methyltransferase 2D (MLL2) was the most frequently mutated chromatin factor in both HPV-negative and HPV-positive HNSCC, with mutation frequencies of 12-17 %. Actin Like 6A (ACTL6A), a component of the SWI/SNF chromatin remodeling complex, was the most frequently copy-number amplified chromatin factor in both HPV-negative and HPV-positive HNSCC, with amplification frequencies of 19-24 %. Double PHD Fingers 1 (DPF1), a component of the chromatin remodeling complex, and Ubiquitin Like With PHD AndRing Finger Domains1 (UHRF1) were the most overexpressed chromatin factors in HPV-negative and HPV-positive HNSCC tumors respectively. Components of the chromatin remodeling complex, such as ACTL6A, SMARCA1 and MORF4L2, were correlated with the "cold" tumor phenotype in both HPV-negative and HPV-positive HNSCC. This brief study highlights epigenetic chromatin factors that may drive oncogenesis and immune evasion, thereby identifying novel targets for cancer therapy in clearly defined, epigenetically-driven subtypes of HPV-negative and HPV-positive HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.